-
Mashup Score: 0Filgotinib Plus Methotrexate Improves Disease Activity, Functional Measures in MTX-IR RA - 2 year(s) ago
“Failed or inadequate response to disease-modifying antirheumatic drugs (DMARDs) is associated with poor prognosis,” investigators noted.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
Objective To characterise safety of the Janus kinase-1 preferential inhibitor filgotinib in patients with moderately to severely active rheumatoid arthritis. Methods Data were integrated from seven trials ([NCT01668641][1], [NCT01894516][2], [NCT02889796][3], [NCT02873936][4], [NCT02886728][5], [NCT02065700][6], [NCT03025308][7]). Results are from placebo (PBO)-controlled (through week (W)12)…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
#Filgotinib 200 and 100 mg are generally well tolerated shows this integrated analysis of safety data from seven clinical trials with #RA patients over a median of 1.6 years 👍 https://t.co/dHpl7STpjN
-
-
Mashup Score: 0
Gastroenterology & Endoscopy News generally avoids coverage of phase 2 trials. After all, preliminary results frequently fail to meet early expectations, and even promising phase 3 data often fail to bring a drug to market.
Source: www.gastroendonews.comCategories: Gastroenterology, Latest HeadlinesTweet-
It’s just a phase: filgotinib for moderately to severely active ulcerative colitis. https://t.co/558fACzJ60 @DCharabaty @HopkinsGIHep #filgotinib #colitis #IBD
-
-
Mashup Score: 9
Gastroenterology & Endoscopy News generally avoids coverage of phase 2 trials. After all, preliminary results frequently fail to meet early expectations, and even promising phase 3 data often fail to bring a drug to market.
Source: www.gastroendonews.comCategories: Gastroenterology, Latest HeadlinesTweet-
The first installment of “It’s Just a Phase” looks at the studies of the preferential JAK1 inhibitor filgotinib, which is in trials as a potential therapy for ulcerative colitis. https://t.co/558fACzJ60 @DCharabaty @HopkinsGIHep #filgotinib #colitis #IBD
-
-
Mashup Score: 27
Filgotinib 200 mg was well tolerated, and efficacious in inducing and maintaining clinical remission compared with placebo in patients with moderately to severely active ulcerative colitis.
Source: The LancetCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
In this study, Brian Feagan et al. report #filgotinib 200 mg was well tolerated and showed efficacy in inducing and maintaining clinical remission compared with placebo in patients with moderately to severely active #ulcerativecolitis. Read https://t.co/b0ehbTSSOr. https://t.co/nwq6ribMcb
-
-
Mashup Score: 13Expanding targeted immune modulators in ulcerative colitis - 3 year(s) ago
Over the past decade, the treatment options for moderately to severely active ulcerative colitis have increased rapidly, with the regulatory approval of multiple non-tumour necrosis factor (TNF)-targeting biologics and small molecule inhibitors, including vedolizumab in 2014, tofacitinib in 2018, and ustekinumab in 2019.1 Among these, tofacitinib (a Janus kinase [JAK]-inhibitor which targets…
Source: The LancetCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
In a linked Comment, @HolmerMd and Siddharth Singh suggest #filgotinib may offer hope to patients and providers for another treatment option for #ulcerativecolitis, but long-term safety will need to be established over time. https://t.co/1rhK2wztJe
-
-
Mashup Score: 1
Filgotinib improves rheumatoid arthritis signs, symptoms and physician function, and inhibits radiographic progression, all while being well-tolerated in patients with an insufficient response to methotrexate, according to data.“Advances in RA management have further improved patient outcomes by focusing on treat-to-target strategies, pain and inflammation reduction, and administration
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
Among #rheumatoidarthritis patients with an inadequate #methotrexate response, #filgotinib was found to improve symptoms, according to findings in @ARD_BMJ https://t.co/friUkVgic1
-
-
Mashup Score: 3
Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active rheumatoid arthritis (RA) despite ongoing treatment with methotrexate (MTX). Methods This 52-week, multicentre, double-blind, placebo-controlled and active-controlled phase III trial evaluated once-daily oral…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
In patients with rheumatoid #arthritis and inadequate response to MTX, #filgotinib reduced signs and symptoms, improved physical function, and inhibited radiographic progression. Read all the details here https://t.co/DBQaWUbCVl
-
-
Mashup Score: 0
Filgotinib improves rheumatoid arthritis signs, symptoms and physician function, and inhibits radiographic progression, all while being well-tolerated in patients with an insufficient response to methotrexate, according to data.“Advances in RA management have further improved patient outcomes by focusing on treat-to-target strategies, pain and inflammation reduction, and administration
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
#Filgotinib improves #rheumatoidarthritis symptoms in patients with inadequate #methotrexate response https://t.co/tm2JFmGCL2 https://t.co/P3GYNwQJXO
-
-
Mashup Score: 0
Filgotinib improves rheumatoid arthritis signs, symptoms and physician function, and inhibits radiographic progression, all while being well-tolerated in patients with an insufficient response to methotrexate, according to data.“Advances in RA management have further improved patient outcomes by focusing on treat-to-target strategies, pain and inflammation reduction, and administration
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
#Filgotinib improves #rheumatoidarthritis signs, symptoms and physician function, and inhibits radiographic progression, all while being well-tolerated in patients with an insufficient response to methotrexate, said researchers @CHU_Montpellier https://t.co/Psys5SP9ld
-
In high-risk patients with #RheumatoidArthritis and inadequate response to methotrexate, #filgotinib treatment demonstrated similar reductions in disease activity when compared with patients with RA at a lower risk at week 12. https://t.co/oBnYlsJNuK